<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638247</url>
  </required_header>
  <id_info>
    <org_study_id>GBG 54</org_study_id>
    <secondary_id>2009-015122-11</secondary_id>
    <nct_id>NCT01638247</nct_id>
  </id_info>
  <brief_title>Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients</brief_title>
  <acronym>MALE</acronym>
  <official_title>A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>German Breast Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or&#xD;
      palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH&#xD;
      analogue in male breast cancer patients (MALE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer in men is a rare disease with approximately 0.5- 1% of all breast cancer cases.&#xD;
      Each year, about 400 to 450 cases are diagnosed in Germany. Men tend to present with more&#xD;
      advanced disease than women, probably due to the lack of awareness of male breast cancer from&#xD;
      both, the patient and the physicians.&#xD;
&#xD;
      Therefore, at presentation they usually have lump or nipple inversion, and more than 40% of&#xD;
      the patients have a stage III or IV disease. The great majority of patients have an invasive&#xD;
      ductal (90%), hormone receptor positive (90%), HER2 negative (90%) tumor.&#xD;
&#xD;
      The only available information on adjuvant therapies derives from few retrospective cases and&#xD;
      retrospective studies with a little number of cases. Therefore, treatment strategies are not&#xD;
      based on data from prospective, randomised clinical studies, and optimal treatment is&#xD;
      unknown. As a result, current clinical management is generally extrapolated from principles&#xD;
      established for the treatment of female breast carcinoma. As the majority of male breast&#xD;
      cancer patients have a hormone receptor positive tumor, they receive tamoxifen 20 mg for five&#xD;
      years as standard endocrine adjuvant therapy. A lot of withdrawals from the treatment were&#xD;
      documented in male breast cancer due to side-effects under tamoxifen therapy. Furthermore,&#xD;
      the clinical outcome of tamoxifen-treated male breast cancer patients may be influenced by&#xD;
      the activity of cytochrome P450 2D6 enzymes that catalyse the formation of anti-estrogenic&#xD;
      metabolites endoxifen and 4-hydroxy-tamoxifen. Therefore a significant proportion of poor to&#xD;
      moderate metaboliser is proposed to do not benefit from adjuvant tamoxifen therapy.&#xD;
&#xD;
      Although women benefit from adjuvant treatment with aromatase inhibitors (AI) regarding&#xD;
      disease-free-survival, overall survival and treatment toxicity, only case reports of men&#xD;
      treated with AI exist. Other data show, that under AI, there is only a suppression of&#xD;
      estradiol of about 40-50% with an increase of testosterone of about 50%. Among men on AIs, it&#xD;
      is possible that the hypothalamic-pituitary feedback loop results in an increase substrate&#xD;
      for aromatisation, and thus prevents complete estrogen suppression.&#xD;
&#xD;
      However, an optimal suppression (80%) of the peripheral estradiol level would be a necessary&#xD;
      condition for a therapeutic benefit of AI in men with breast cancer.&#xD;
&#xD;
      By adding a gonadotropin-releasing hormone analogue, the negative feedback loop would be&#xD;
      interrupted and complete estrogen suppression may be achieved.&#xD;
&#xD;
      In conclusion, there is a great lack on information for the treatment of male patients with&#xD;
      breast cancer.&#xD;
&#xD;
      Prospective multi-centre, randomised trials in men with breast cancer are necessary in order&#xD;
      to prove the effect of tamoxifen + GnRH analogue versus none and versus AI + GnRH analogue as&#xD;
      adjuvant or neoadjuvant endocrine treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estradiol blood concentation</measure>
    <time_frame>3 months.</time_frame>
    <description>To determine the estradiol suppression between the three treatment arms after three months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estradiol blood concentration</measure>
    <time_frame>6 months.</time_frame>
    <description>To determine the estradiol suppression between the three treatment arms after six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>6 months.</time_frame>
    <description>To compare the compliance in the three treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 months.</time_frame>
    <description>To compare the efficacy in terms of overall response (for neoadjuvant and metastatic patients) in the three treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy perameters</measure>
    <time_frame>6 months.</time_frame>
    <description>To compare testosterone, dihydrotestosterone (DHT), SHBG, FSH, LH, osteocalcin and CTX in the three treatments arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and side effect parameters</measure>
    <time_frame>6 months.</time_frame>
    <description>To determine the safety and side effect parameters (at every visit):&#xD;
PSA and hemoglobin.&#xD;
Lipids (total cholesterol, high density lipid cholesterol, low density lipid cholesterol).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Male Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamoxifen alone (daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen and GnRH analogue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen (daily) + GnRH analogue (at randomisation and after three months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exemestane and GnRH analogue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exemestane (daily) + GnRH analogue (at randomisation and after three months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>25 mg daily.</description>
    <arm_group_label>Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen and GnRH analogue</intervention_name>
    <description>25 mg Tamoxifen daily and GnRH analogue:&#xD;
Goserelin (10.8 mg s.c. after randomisation and after three months) or&#xD;
Leuprorelin (11.25 mg s.c. after randomisation and after three months).</description>
    <arm_group_label>Tamoxifen and GnRH analogue</arm_group_label>
    <other_name>TRENATONE, ZOLADEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane and GnRH analogue</intervention_name>
    <description>25 mg Exemestane daily and GnRH analogue:&#xD;
Goserelin (10.8 mg s.c. after randomisation and after three months) or&#xD;
Leuprorelin (11.25 mg s.c. after randomisation and after three months).</description>
    <arm_group_label>Exemestane and GnRH analogue</arm_group_label>
    <other_name>AROMASIN, TRENATONE, ZOLADEX.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Written informed consent for all study procedures.&#xD;
&#xD;
          2. Complete baseline documentation sent to GBG Forschungs GmbH.&#xD;
&#xD;
          3. Male patients.&#xD;
&#xD;
          4. Age ≥ 18 years.&#xD;
&#xD;
          5. Karnofsky-Index ≥ 60%.&#xD;
&#xD;
          6. Histologically confirmed unilateral or bilateral carcinoma or of the breast at primary&#xD;
             diagnosis (enrolment possible in neoadjuvant, adjuvant and metastatic situation).&#xD;
&#xD;
        7: No target lesion necessary for metastatic situation 8. Positive hormone receptor status&#xD;
        (e.g. ER and/or PR-receptor positive). 9. Completed staging prior randomisation ( within 8&#xD;
        weeks after diagnose or last therapy (operation, chemotherapy or radiation), minimum: chest&#xD;
        X-ray, ultrasound of the liver, bone scan).&#xD;
&#xD;
        In case of positive findings, further investigations are required to verify the findings as&#xD;
        clinically indicated.&#xD;
&#xD;
        10. Prior chemotherapy is possible. In case of adjuvant treatment: adequate surgical&#xD;
        treatment with histological complete resection including axillary lymph nodes if patients&#xD;
        are included as adjuvant treatment. A sentinel lymph node biopsy is possible if the&#xD;
        sentinel is not involved.&#xD;
&#xD;
        11. Normal cardiac function must be confirmed by ECG within three months prior to&#xD;
        randomisation.&#xD;
&#xD;
        12. Laboratory requirements (≤ 14 days before therapy start): Hematology&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL,&#xD;
&#xD;
          -  Leukocytes 4 - 10 x1000/µL,&#xD;
&#xD;
          -  Thrombocytes 150 - 400 x1000/µL. Hepatic function&#xD;
&#xD;
          -  ASAT (SGOT) or ALAT (SGPT) ≤ 2x UNL,&#xD;
&#xD;
          -  Total bilirubin ≤ 2x UNL. Renal function&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5x UNL,&#xD;
&#xD;
          -  Creatinine clearance &gt; 30 mL/min (if creatinine is above UNL, according to&#xD;
             Cockroft-Gault).&#xD;
&#xD;
          -  Cholesterol 200 - 240 mg/dL (5.18 - 6.22 mmol/L),&#xD;
&#xD;
          -  HDL cholesterol &gt; 40 mg/dL (&gt; 1 mmol/L),&#xD;
&#xD;
          -  LDL cholesterol ≤ 160 mg/dL (≤ 4 mmol/L).&#xD;
&#xD;
          -  Prostate specific antigen (PSA) ≤ 2.5 ng/mL. 13. Two serum samples (5 mL) centrally&#xD;
             made available. 14. Paraffin tumor tissue block and full blood sample centrally made&#xD;
             available (except when the patient does not agree to central biomaterial collection).&#xD;
&#xD;
             15. The patient must be accessible for treatment. Patients can simultaneously be&#xD;
             registered in the register study of the University Hospital of Magdeburg.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Female patients.&#xD;
&#xD;
          2. Prior endocrine therapy of breast carcinoma.&#xD;
&#xD;
          3. Known or suspected hypersensitivity reaction to the compounds or incorporated&#xD;
             substances.&#xD;
&#xD;
          4. No indication for endocrine treatment.&#xD;
&#xD;
          5. Life expectancy of less than six months.&#xD;
&#xD;
          6. International Prostate Symptom Score (IPSS) &gt; 17.&#xD;
&#xD;
          7. Current diagnosis of a Prostate carcinoma.&#xD;
&#xD;
          8. History of prostate cancer within the last five years and regardless the time frame&#xD;
             all patients with hormone receptor positive prostate carcinoma who have received&#xD;
             endocrine treatment.&#xD;
&#xD;
          9. Concurrent neuronal or cardiac disease, poorly controlled arterial hypertension.&#xD;
&#xD;
         10. Previous thromboembolic event within the last five years (except from thromboembolic&#xD;
             events correlated to implanted devices (e.g. port thrombosis)&#xD;
&#xD;
         11. Currently active hepatitis.&#xD;
&#xD;
         12. Disease significantly affecting gastrointestinal function, e.g. malabsorption&#xD;
             syndrome, resection of the stomach or small bowel.&#xD;
&#xD;
         13. Concurrent treatment with other experimental drugs or participation in another&#xD;
             clinical trial with any investigational, not marketed drug within 30 days prior to&#xD;
             study entry.&#xD;
&#xD;
         14. Patients who are not able to give informed consent as defined according to AMG.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mattea Reinisch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kliniken Essen-Mitte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.gbg.de/de/studien/male.php</url>
    <description>Sponsor study homepage</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Male breast cancer</keyword>
  <keyword>neoadjuvant, adjuvant or metastatic situation</keyword>
  <keyword>anti-hormonal therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

